Background: Anti‐centromere autoantibodies (ACA) are frequently detected in systemic
sclerosis (SScl), especially in the calcinosis, Raynaud phenomenon, esophageal …

Objective To clarify the clinical significance of anticentromere antibodies (ACA) in patients
with systemic lupus erythematosus (SLE). Methods Two hundred sixteen patients with SLE …

Objective. To evaluate an enzyme‐linked immunosorbent assay (ELISA) for anticentromere
autoantibodies (ACA). Methods. Sera from 611 patients with scleroderma, CREST …

The objective of this study was to determine the clinical features of 44 patients with
anticentromere antibody (ACA) positivity. We undertook a retrospective review of 44 ACA …

Anticentromere antibodies identified by indirect immunofluorescence are a valuable aid to
the diagnosis and prognosis of patients with systemic sclerosis since they are associated in …

OBJECTIVE: To evaluate the clinical and serological heterogeneity in patients with
anticentromere antibodies (ACA). METHODS: One hundred twenty patients with ACA were …

Introduction Anti-centromere antibodies (ACA) are useful biomarkers in the diagnosis of
systemic sclerosis (SSc) where they are found in 20–40% of patients and, albeit with lower …

Anticentromere autoantibodies (ACA) are associated with Raynaud's disease and systemic
sclerosis (SSc). ACA usually bind at least one of three major centromere proteins (CENPs) …

Conclusion ACA are directed towards centromeric proteins (CENP) with MW of 17 KD
(CENP-A), 80 KD (CENP-B) and 140 KD (CENP-C). At least 6 epitopes on these proteins …

Anticentromere antibodies (ACA) are useful in assessing and classifying patients with mild
variant of systemic sclerosis called calcinosis, Raynaud's phenomenon, esophageal …